Foundry Partners LLC Acquires 133 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Foundry Partners LLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,103 shares of the medical equipment provider’s stock after buying an additional 133 shares during the quarter. Foundry Partners LLC’s holdings in Lantheus were worth $278,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cynosure Group LLC boosted its position in Lantheus by 9.2% in the 4th quarter. Cynosure Group LLC now owns 3,558 shares of the medical equipment provider’s stock valued at $318,000 after buying an additional 299 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Lantheus by 37.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 323,900 shares of the medical equipment provider’s stock valued at $28,976,000 after acquiring an additional 87,412 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Lantheus in the fourth quarter valued at approximately $7,238,000. Wellington Management Group LLP bought a new position in Lantheus in the fourth quarter worth approximately $20,022,000. Finally, Summit Securities Group LLC purchased a new position in Lantheus during the 4th quarter worth $37,000. 99.06% of the stock is owned by institutional investors.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 over the last 90 days. 2.00% of the stock is currently owned by corporate insiders.

Lantheus Stock Down 6.5 %

NASDAQ:LNTH opened at $90.92 on Friday. The stock has a market capitalization of $6.23 billion, a price-to-earnings ratio of 15.13 and a beta of 0.38. Lantheus Holdings, Inc. has a 52 week low of $58.46 and a 52 week high of $126.89. The firm has a 50 day moving average of $93.31 and a 200 day moving average of $96.12.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LNTH. JMP Securities reiterated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial upped their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday, March 21st. Finally, The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $129.43.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.